{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:42:21Z","timestamp":1791229341256,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,15]]},"DOI":"10.7759\/cureus.87983","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:06:08Z","timestamp":1752584768000},"source":"Crossref","is-referenced-by-count":6,"title":["Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence"],"prefix":"10.7759","author":[{"given":"Hansan L","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore I","family":"Nania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian M","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec W","family":"Lyons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ashurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Holley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116472","article-title":"Comprehensive literature review on the prevalence of comorbid conditions in patients with achondroplasia","volume":"162","author":"Stender M","year":"2022","unstructured":"Stender M, Pimenta JM, Cheung M, Irving M, Mukherjee S. Comprehensive literature review on the prevalence of comorbid conditions in patients with achondroplasia. Bone. 2022, 162:116472. 10.1016\/j.bone.2022.116472","journal-title":"Bone"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100843","article-title":"Lifetime impact study for achondroplasia (LISA): findings from an observational and multinational study focused on health-related quality of life in individuals with achondroplasia in Latin America","volume":"2","author":"Llerena J Jr","year":"2024","unstructured":"Llerena J Jr, Rosselli P, Arag\u00e3o A, et al.. Lifetime impact study for achondroplasia (LISA): findings from an observational and multinational study focused on health-related quality of life in individuals with achondroplasia in Latin America. Genet Med Open. 2024, 2:100843. 10.1016\/j.gimo.2023.100843","journal-title":"Genet Med Open"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000074503","article-title":"Molecular basis for the treatment of achondroplasia","volume":"60","author":"Yamanaka Y","year":"2003","unstructured":"Yamanaka Y, Ueda K, Seino Y, Tanaka H. Molecular basis for the treatment of achondroplasia. Horm Res. 2003, 60:60-4. 10.1159\/000074503","journal-title":"Horm Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100771","article-title":"Vosoritide approved for treatment of linear growth in pediatric patients with achondroplasia: a therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG)","volume":"1","author":"Poskanzer SA","year":"2023","unstructured":"Poskanzer SA, Pe\u00f1a LD, Niu Z. Vosoritide approved for treatment of linear growth in pediatric patients with achondroplasia: a therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG). Genet Med Open. 2023, 1:100771. 10.1016\/j.gimo.2023.100771","journal-title":"Genet Med Open"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.11.019","article-title":"Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study","volume":"6","author":"Savarirayan R","year":"2025","unstructured":"Savarirayan R, Irving M, Wilcox WR, et al.. Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study. Med. 2025, 6:100566. 10.1016\/j.medj.2024.11.019","journal-title":"Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-024-01074-9","article-title":"International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia","volume":"21","author":"Savarirayan R","year":"2025","unstructured":"Savarirayan R, Hoover-Fong J, Ozono K, et al.. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat Rev Endocrinol. 2025, 21:314-24. 10.1038\/s41574-024-01074-9","journal-title":"Nat Rev Endocrinol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31541-5","article-title":"Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial","volume":"396","author":"Savarirayan R","year":"2020","unstructured":"Savarirayan R, Tofts L, Irving M, et al.. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020, 396:684-92. 10.1016\/S0140-6736(20)31541-5","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000446958","article-title":"Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis","volume":"86","author":"Miccoli M","year":"2016","unstructured":"Miccoli M, Bertelloni S, Massart F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis. Horm Res Paediatr. 2016, 86:27-34. 10.1159\/000446958","journal-title":"Horm Res Paediatr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115573","article-title":"Advantages and disadvantages of different treatment methods in achondroplasia: a review","volume":"22","author":"Wrobel W","year":"2021","unstructured":"Wrobel W, Pach E, Ben-Skowronek I. Advantages and disadvantages of different treatment methods in achondroplasia: a review. Int J Mol Sci. 2021, 22:5573. 10.3390\/ijms22115573","journal-title":"Int J Mol Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02738-x","article-title":"Achondroplasia natural history study (CLARITY): 60-year experience in orthopedic surgery from four skeletal dysplasia centers","volume":"18","author":"Nahm NJ","year":"2023","unstructured":"Nahm NJ, Mackenzie WG, Mackenzie WG, et al.. Achondroplasia natural history study (CLARITY): 60-year experience in orthopedic surgery from four skeletal dysplasia centers. Orphanet J Rare Dis. 2023, 18:139. 10.1186\/s13023-023-02738-x","journal-title":"Orphanet J Rare Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1281099","article-title":"Results and complications of bilateral limb lengthening in achondroplasia: a retrospective analysis","volume":"11","author":"Verdoni F","year":"2023","unstructured":"Verdoni F, Giorgino R, Virgilio C, et al.. Results and complications of bilateral limb lengthening in achondroplasia: a retrospective analysis. Front Pediatr. 2023, 11:1281099. 10.3389\/fped.2023.1281099","journal-title":"Front Pediatr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/CORR.0000000000002209","article-title":"What are the risks and functional outcomes associated with bilateral humeral lengthening using a monolateral external fixator in patients with achondroplasia?","volume":"480","author":"Laufer A","year":"2022","unstructured":"Laufer A, R\u00f6lfing JD, Gosheger G, Toporowski G, Frommer A, Roedl R, Vogt B. What are the risks and functional outcomes associated with bilateral humeral lengthening using a monolateral external fixator in patients with achondroplasia?. Clin Orthop Relat Res. 2022, 480:1779-89. 10.1097\/CORR.0000000000002209","journal-title":"Clin Orthop Relat Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.21037\/tp-24-249","article-title":"Assessment of the efficacy of vosoritide therapy in children with achondroplasia in clinical trials","volume":"13","author":"Wrobel W","year":"2024","unstructured":"Wrobel W, Ben-Skowronek I. Assessment of the efficacy of vosoritide therapy in children with achondroplasia in clinical trials. Transl Pediatr. 2024, 13:1515-6. 10.21037\/tp-24-249","journal-title":"Transl Pediatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5582\/irdr.2023.01055","article-title":"Vosoritide, a miracle drug, covering unmet need in achondroplasia: a regulatory update","volume":"12","author":"Simran","year":"2023","unstructured":"Simran, Kirthiga Devi SS, Dushantrao SC, Joga R, Kumar S. Vosoritide, a miracle drug, covering unmet need in achondroplasia: a regulatory update. Intractable Rare Dis Res. 2023, 12:257-61. 10.5582\/irdr.2023.01055","journal-title":"Intractable Rare Dis Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/children11070789","article-title":"Consensus guidelines for the use of vosoritide in children with achondroplasia in Australia","volume":"11","author":"Tofts L","year":"2024","unstructured":"Tofts L, Ireland P, Tate T, et al.. Consensus guidelines for the use of vosoritide in children with achondroplasia in Australia. Children (Basel). 2024, 11:789. 10.3390\/children11070789","journal-title":"Children (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1159\/000543743","article-title":"Real-world safety and effectiveness of vosoritide in children with achondroplasia: French early access program","author":"Cormier-Daire V","year":"2025","unstructured":"Cormier-Daire V, Edouard T, Isidor B, et al.. Real-world safety and effectiveness of vosoritide in children with achondroplasia: French early access program. Horm Res Paediatr. 2025, 1-9. 10.1159\/000543743","journal-title":"Horm Res Paediatr"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf041","article-title":"Real-world outcome of vosoritide treatment in children with achondroplasia: a 12-month retrospective observational study","volume":"9","author":"Reincke S","year":"2025","unstructured":"Reincke S, Semler O, Jungh\u00e4nel-Welzing S, Stasek S, Rehberg M, Pfeiffer E, Hoyer-Kuhn H. Real-world outcome of vosoritide treatment in children with achondroplasia: a 12-month retrospective observational study. J Endocr Soc. 2025, 9:bvaf041. 10.1210\/jendso\/bvaf041","journal-title":"J Endocr Soc"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/BPO.0000000000002980","article-title":"Changes in the alignment of the spine and lower limb in children with achondroplasia treated with vosoritide: a single-center, 1-year follow-up prospective study","volume":"0","author":"Sawamura K","year":"2025","unstructured":"Sawamura K, Kitoh H, Kamiya Y, Mishima K, Matsushita M, Imagama S. Changes in the alignment of the spine and lower limb in children with achondroplasia treated with vosoritide: a single-center, 1-year follow-up prospective study. J Pediatr Orthop. 2025, 0:0. 10.1097\/BPO.0000000000002980","journal-title":"J Pediatr Orthop"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-025-05231-0","article-title":"Hypertrichosis associated with the use of C-type natriuretic peptide analogue: a case report","volume":"19","author":"Clinton JL Jr","year":"2025","unstructured":"Clinton JL Jr, Magalhaes TS, Bordallo AP, Collett-Solberg PF. Hypertrichosis associated with the use of C-type natriuretic peptide analogue: a case report. J Med Case Rep. 2025, 19:185. 10.1186\/s13256-025-05231-0","journal-title":"J Med Case Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59695","article-title":"Two cases of cardiovascular adverse events following subcutaneous vosoritide injection in early infancy","volume":"16","author":"Nishioka A","year":"2024","unstructured":"Nishioka A, Adachi N, Tanaka H, Oda Y. Two cases of cardiovascular adverse events following subcutaneous vosoritide injection in early infancy. Cureus. 2024, 16:e59695. 10.7759\/cureus.59695","journal-title":"Cureus"},{"key":"ref21","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn Z","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, et al.. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evidence Synthesis. 2020, 18:2127-33.","journal-title":"JBI Evidence Synthesis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.64054","article-title":"Functional change in a child with achondroplasia following 12 months treatment with vosoritide-a case report","volume":"197","author":"Ireland P","year":"2025","unstructured":"Ireland P, Carroll T, Pendlebury E, Weston E, Munns C. Functional change in a child with achondroplasia following 12 months treatment with vosoritide-a case report. Am J Med Genet A. 2025, 197:e64054. 10.1002\/ajmg.a.64054","journal-title":"Am J Med Genet A"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/ped.70089","article-title":"An infant with achondroplasia worsening of the foramen magnum stenosis during early vosoritide treatment","volume":"67","author":"Gunji Y","year":"2025","unstructured":"Gunji Y, Aoki R, Nagano N, Aoki M, Okahashi A, Sumi K, Morioka I. An infant with achondroplasia worsening of the foramen magnum stenosis during early vosoritide treatment. Pediatr Int. 2025, 67:e70089. 10.1111\/ped.70089","journal-title":"Pediatr Int"},{"key":"ref24","article-title":"Chapter 7: Systematic reviews of etiology and risk","author":"Moola S","year":"2020","unstructured":"Moola S, Munn Z, Tufanaru C, et al.. Chapter 7: Systematic reviews of etiology and risk. JBI Evidence Synthesis. Joanna Briggs Institute, Adelaide, South Australia; 2020."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01059-1","article-title":"Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia","volume":"61","author":"Chan ML","year":"2022","unstructured":"Chan ML, Qi Y, Larimore K, et al.. Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia. Clin Pharmacokinet. 2022, 61:263-80. 10.1007\/s40262-021-01059-1","journal-title":"Clin Pharmacokinet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100223","article-title":"P194: persistence of growth promoting effects in children with achondroplasia over seven years: update from phase II extension study with vosoritide*","volume":"1","author":"Hoover-Fong J","year":"2023","unstructured":"Hoover-Fong J, Irving M, Bacino C, et al.. P194: persistence of growth promoting effects in children with achondroplasia over seven years: update from phase II extension study with vosoritide*. Genet Med Open. 2023, 1:100223. 10.1016\/j.gimo.2023.100223","journal-title":"Genet Med Open"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(23)00265-1","article-title":"Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Savarirayan R","year":"2024","unstructured":"Savarirayan R, Wilcox WR, Harmatz P, et al.. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc Health. 2024, 8:40-50. 10.1016\/S2352-4642(23)00265-1","journal-title":"Lancet Child Adolesc Health"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000003007","article-title":"Association between radiological severity of lumbar spinal stenosis and spinopelvic parameters in adult patients with achondroplasia","volume":"95","author":"Cai H","year":"2024","unstructured":"Cai H, Omara C, Vleggeert-Lankamp CL. Association between radiological severity of lumbar spinal stenosis and spinopelvic parameters in adult patients with achondroplasia. Neurosurgery. 2024, 95:1317-28. 10.1227\/neu.0000000000003007","journal-title":"Neurosurgery"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01287-7","article-title":"Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study","volume":"23","author":"Savarirayan R","year":"2021","unstructured":"Savarirayan R, Tofts L, Irving M, et al.. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet Med. 2021, 23:2443-7. 10.1038\/s41436-021-01287-7","journal-title":"Genet Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02496-z","article-title":"Parents\u2019 experience of administering vosoritide: a daily injectable for children with achondroplasia","volume":"40","author":"NiMhurchadha S","year":"2023","unstructured":"NiMhurchadha S, Butler K, Argent R, Palm K, Baujat G, Cormier-Daire V, Mohnike K. Parents\u2019 experience of administering vosoritide: a daily injectable for children with achondroplasia. Adv Ther. 2023, 40:2457-70. 10.1007\/s12325-023-02496-z","journal-title":"Adv Ther"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02705-9","article-title":"Vosoritide therapy in children with achondroplasia: early experience and practical considerations for clinical practice","volume":"41","author":"Semler O","year":"2024","unstructured":"Semler O, Cormier-Daire V, Lausch E, et al.. Vosoritide therapy in children with achondroplasia: early experience and practical considerations for clinical practice. Adv Ther. 2024, 41:198-214. 10.1007\/s12325-023-02705-9","journal-title":"Adv Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/380901-vosoritide-voxzogo-for-achondroplasia-a-review-of-clinical-and-real-world-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T13:06:09Z","timestamp":1752584769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/380901-vosoritide-voxzogo-for-achondroplasia-a-review-of-clinical-and-real-world-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":31,"URL":"https:\/\/doi.org\/10.7759\/cureus.87983","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,15]]}}}